Go to the search | Go to the navigation | Go to the Content

EUROTRANS-BIO initiative joins partners from:
Austria, Basque Country (Spain), Flanders (Belgium), Finland, France, Germany, Italy, and The Netherlands. Wallonia (Belgium), Hungary, Catalonia (Spain) and the Madrid* Region (Spain) joined the consortium for the EUROTRANS-BIO 4th call.

* Participation of Madrid Region is not confirmed; the possible participation of Madrid Region in the ETB call will be notified by 30.1.2009

Home

EUROTRANS-BIO TRANSNATIONAL CALL

Latest News

EUROTRANSBIO opens the
5th Transnational Call for Proposals
on the October 1st 2009

  • The strategic objective of the 5th ETB call is to foster the competitive capacity Europe’s biotechnology industry by supporting the research intensive SMEs and their strategic partnerships. The ETB call 2010 is a generic call including all fields of biotechnology.
  • The 5th ETB Call is launched with the participation of 12 EU Countries and Regions.
    -  Countries: Austria, Finland, France, Germany, Hungary, Italy, The Netherlands
    -  Regions: Basque Country (Spain), Catalonia (Spain), Madrid (Spain), Flanders (Belgium), Wallonia (Belgium).

5th call helpdesk

All the information necessary to the submission is available on the 5th call helpdesk page. ETB has created a partnering site to facilitate the match making of partners for an ETB consortium.

If you are looking for a partner for your ETB project or if you are looking for a project to join, visit the ETB partnering webpage https://www.etbsubmission.eu/etbsubmission/partner/ and fill in your project description and contact details. This additional option may help you to build a consortium. For further information on completing a project/ partner search, visit the partnering site webpage.

ETB Electronic Submission System (ESS)

If you want to submit your proposal please visit the ETB ESS.

You are advised NOT to wait until the last moment before registering and submitting your proposal!

TESTIMONY

  • Here you can read a testimony of the Dutch Company Merus BV, who received an ETB grant worth of € 0.67 million and financed via the "Life Science and Health" innovation program of SenterNovem (NL). This grant will enable Merus BV to develop innovative combinations of human therapeutic antibodies for the treatment of chronic inflammatory diseases. Merus testimony (PDF - 64KB)